- Home
- XYL vs KVUE Comparison
XYL vs KVUE Comparison
Compare XYL & KVUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XYL | KVUE |
|---|---|---|
| Founded | 2011 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Fluid Controls | Specialty Chemicals |
| Sector | Industrials | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.2B | 33.7B |
| IPO Year | 2011 | 2023 |
Fundamental Metrics
Financial Performance| Metric | XYL | KVUE |
|---|---|---|
| Price | $116.58 | $17.39 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 11 |
| Target Price | ★ $152.50 | $19.45 |
| AVG Volume (30 Days) | 2.3M | ★ 14.8M |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | 1.49% | ★ 4.82% |
| EPS Growth | 7.40 | ★ 40.74 |
| EPS | ★ 0.79 | 0.76 |
| Revenue | $9,035,000,000.00 | ★ $15,124,000,000.00 |
| Revenue This Year | $2.79 | $4.85 |
| Revenue Next Year | $4.49 | $2.63 |
| P/E Ratio | $145.52 | ★ $22.51 |
| Revenue Growth | ★ 5.52 | N/A |
| 52 Week Low | $114.15 | $14.02 |
| 52 Week High | $154.27 | $25.17 |
Technical Indicators
Market Signals| Indicator | XYL | KVUE |
|---|---|---|
| Relative Strength Index (RSI) | 41.03 | 49.19 |
| Support Level | N/A | $17.20 |
| Resistance Level | $141.89 | $17.75 |
| Average True Range (ATR) | 3.03 | 0.32 |
| MACD | -0.69 | 0.01 |
| Stochastic Oscillator | 20.22 | 48.17 |
Price Performance
Historical ComparisonAbout XYL Xylem Inc. New
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $9 billion in revenue in 2025.
About KVUE Kenvue Inc.
Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of categories within consumer health, such as cough, cold, and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Kenvue announced in November 2025 that it signed a deal to be fully acquired by Kimberly-Clark, with the deal expected to close during the second half of 2026.